Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

Walter Taal, Hendrika M. Oosterkamp, Annemiek Walenkamp, Hendrikus J. Dubbink, Laurens V. Beerepoot, Monique C.J. Hanse, Jan Buter, Aafke H. Honkoop, Dolf Boerman, Filip De Vos,

The Lancet Oncology · 2014 · 753 citations · 33 references

Concepts

References

33